Announcing a new article publication for Cardiovascular Innovations and Applications journal. Radiation-induced cardiomyopathy has become a significant clinical challenge with the increased use of ...

The sudden death of a UNLV football player leaves the community seeking answers while young athletes reevaluate their own health.A report from the Las Vegas Met ...

Tirzepatide is just as effective in reducing cardiovascular risk driven by central adiposity as that driven by general ...

The device has evolved from one aimed at just functional MR to a broader HF therapy. EMPOWER will provide more insights.

Longview Regional Medical Center has scheduled free heart screenings Saturday for area youth ages 14 to 18. The screenings ...

Prescription totals for Attruby, which is locked in a closely watched commercial battle with Pfizer’s tafamidis, have more ...

Scotiabank raised the firm’s price target on BridgeBio (BBIO) to $52 from $49 and keeps an Outperform rating on the shares. The company’s ...

Researchers at the Yale School of Medicine (YSM) have developed a new screening test that pairs AI with portable cardiac ...

Gregg Stone cast doubt on its reliability in trials, while David Cohen said QoL matters to patients and should be measured.

Despite the prevalence of cardiovascular disease, many people are unclear about the role their genes play and how to lower their risk.

BridgeBio beat investor expectations with 1,028 unique prescriptions for ATTR-CM therapy Attruby, setting the company up to ...